Interleukin-4 (IL-4) is a pleiotropic cytokine with broad spectrum of biological effects on target cells. This study deals with the mammalian expression of canine IL-4 (cIL-4) in canine articular chondrocytes (CAC) and its ability to down-regulate pro-inflammatory cytokines, enzyme mediators and their catabolites. We transfected cIL-4 in CAC which were then stimulated with canine recombinant IL-1beta and TNFalpha or left as untreated control CAC. The cIL-4 protein was detected by Western blot analysis and quantified by sandwich ELISA utilizing monoclonal and polyclonal antibodies raised against recombinant cIL-4. Pro-inflammatory cytokines and enzyme mediators were quantified by quantitative real-time PCR, and nitrite production was measured by a calorimetric assay. Our results show that cIL-4 is expressed in CAC as a 17kD protein, which inhibits various cytokines and inflammatory mediators when stimulated by IL-1beta and TNFalpha. Thus, cIL-4 expressed in CAC is biologically active and suppresses inflammatory mediators in vitro. Since STAT6 (signal transducer and activator of transcription 6) was solely expressed in transfected CAC and not at all detectable in control cells, it is likely that IL-4 exerts its anti-inflammatory effects through STAT6 signaling. These studies allowed us to identify the canine form of STAT6 which we have partially sequenced.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cyto.2008.07.470 | DOI Listing |
Mob DNA
January 2025
Department of Biology, La Sierra University, Riverside, CA, USA.
Background: Messenger RNA 3' untranslated regions (3'UTRs) control many aspects of gene expression and determine where the transcript will terminate. The polyadenylation signal (PAS) AAUAAA (AATAAA in DNA) is a key regulator of transcript termination and this hexamer, or a similar sequence, is very frequently found within 30 bp of 3'UTR ends. Short interspersed element (SINE) retrotransposons are found throughout genomes in high copy numbers.
View Article and Find Full Text PDFCancer Immunol Immunother
January 2025
Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Histiocytic sarcoma (HS) is a rare yet lethal malignancy with no established standard of care therapies. A lack of pre-clinical models limits our understanding of HS pathogenesis and identification of therapeutic targets. Canine HS shares multiple clinical and genetic similarities with human HS, supporting its use as a unique translational model.
View Article and Find Full Text PDFBiomater Sci
January 2025
Department of Periodontology, College of Dentistry and Institute of Oral Bioscience, Jeonbuk National University, Jeonju, Republic of Korea.
Infected alveolar bone defects pose challenging clinical issues due to disrupted intrinsic healing mechanisms. Thus, the employment of advanced biomaterials enabling the modulation of several aspects of bone regeneration is necessary. This study investigated the effect of multi-functional nanoparticles on anti-inflammatory/osteoconductive characteristics and bone repair in the context of inflamed bone abnormalities.
View Article and Find Full Text PDFIn Vivo
December 2024
Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan;
Background/aim: Soft tissue sarcoma (STS) is a mesenchymal tumor affecting multiple organs in dogs. Previous studies identified activation of the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (PKB, AKT) pathway in canine STS cell lines and clinical samples, but the underlying mechanism remains unclear. This study investigated PTEN loss, PIK3CA mutation, and EGFR over-expression as potential drivers of PI3K/AKT pathway activation in STS.
View Article and Find Full Text PDFPLoS One
December 2024
Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.
Appendicular central osteosarcoma (OSA) is a common and highly aggressive tumour in dogs. Metastatic disease to the lungs is common and even with chemotherapy the prognosis is generally poor. However, few cases survive well beyond reported median survival times.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!